EPS eLibrary: STUDY THE CHEMOPREVENTIVE EFFICACY OF NEW IODINE COMPLEX ON CANCER MICE AND COMPATIBILITY OF TABLET EXCIPIENTS

Peer-reviewed articles 17,970 +

Proceedings Cover

Title: STUDY THE CHEMOPREVENTIVE EFFICACY OF NEW IODINE COMPLEX ON CANCER MICE AND COMPATIBILITY OF TABLET EXCIPIENTS

Year

2020

BibTex Views:

1753

Peer Reviewed

Open this article in the author's DB

<< Back to list

Title

STUDY THE CHEMOPREVENTIVE EFFICACY OF NEW IODINE COMPLEX ON CANCER MICE AND COMPATIBILITY OF TABLET EXCIPIENTS

PlumX Article Metrics by Elsevier

Authors

Assima O. Abekova;Aissulu Kabdraisova;Rinat Islamov;Аlexander I. Ilin

DOI

DOI Issue

ISSN

ISBN

Language

English

Volume

Issue

Editor

Scientific Area

Abstract/ Foreword

It is well known that the iodine solution has a potent anticancer activity. However, the usage of this solution is not so common in clinical practice due to its high chemical activity and its role in the formation of ulcers on the surface of mucous membranes. Nevertheless, there are several new and promising drugs that can act as perfect candidates for anticancer therapy. One such candidate is a formation of polyiodide in complex with ?-dextrin, potassium, and lithium halides. Combined together, these properties make up a new complex structure known as KC-144, which acts as an active pharmaceutical ingredient. The aims of this study were to investigate the effect of KC-144 on an in vitro model of breast cancer cell line (MCF-7) in terms of proliferation potential using well known MTT assay and to use Balb/c SPF mouse model to observe the effectiveness of benzo(a)pyrene BP as a chemopreventative agent in lung cancer. KС-144 was administered daily intragastrical at doses of 2.5 and 25 mg/kg (total iodine) for 2 weeks before and after BP treatment. Moreover, we evaluated the drug-excipient compatibility using differential scanning calorimetry (DSC), infrared (IR) spectrophotometer, and UV spectroscopy.
The results show that the exposure to KC-144 at the minimum and maximum doses significantly increases the mean survival time (MST) of animals, 126 ± 13, and 119 ± 17 days, respectively. Interestingly, MST among mice, which did not receive KC-144 treatment, was only 94 ± 13 days. In addition, the results of the DSC study have shown that microcrystalline cellulose, lactose monohydrate and ?-cyclodextrin exhibited some interaction with KC-144. However, the results of IR and UV spectroscopy studies showed that basically all the excipients used in the formulation were compatible with KC-144. The best results were obtained with lactose monohydrate in a 1: 1 ratio.